Lakefront Biotherapeutics reported a net profit of €13.9 million for the first nine months of 2026, a significant turnaround from a €461.3 million loss in the same period last year. The company highlighted progress with its autoimmune drug gamgertamig, which showed promising Phase 1b study results and received Orphan Drug Designation from the FDA. Lakefront completed a €50 million share repurchase program and announced a second €50 million buyback to be completed by Q1 2027. The company expects year-end cash and financial investments of at least €2 billion and plans to shift its reporting currency to the U.S. dollar in 2027.
Lakefront Biotherapeutics financial results provide context for readers. For those tracking health stocks, 77 of 150 US health-sector stocks rose and 73 fell on Pluang. Notable movers as of Nov 12, 2026 01:21 WIB include LQDA at USD 56.09 (+9.12%), NUWE at USD 5.68 (+8.40%), and TNGX at USD 26.34 (+8.40%).
The global beverage market is projected to grow from $2.03 trillion in 2026 to $2.78 trillion by 2032, at a CAGR of 5.35%. Growth is fueled by rising demand for nonalcoholic and functional beverages, convenience packaging, and premium products for sp...
DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...
Pyth Network has integrated real-time stock and ETF data from five NYSE exchanges into its marketplace, enhancing its institutional market-data services. This expansion follows its earlier Nasdaq integration, providing developers a unified source for...
Innovative Holdings Alliance, Inc. has changed its name to Premergy, Inc. and will trade under the new ticker symbol PMGY starting November 12, 2026. This rebranding aligns the company with its focus on advanced battery technology and power-managemen...
AMH announced a dividend of $0.33 per common share for Q4 2026, payable in cash on December 31 to shareholders of record as of December 15. Additionally, quarterly distributions were declared for preferred shares: $0.36719 for Series G and $0.39063 f...
